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A B S T R A C T
The aim of this prospective clinical study was to investigate the intraocular pressure
(IOP) reduction after selective laser trabeculoplasty (SLT) in patients with primary
open-angle glaucoma (POAG). SLT represents a new method in the treatment of POAG.
Fifty eyes with uncontrolled POAG were treated with a frequency doubled, Q-switched
Nd:YAG laser (532 nm). The pattern of treatment was applying approximately 50 burns
to 180 degrees of the trabecular meshwork at energy levels ranging from 0.40– 0.92 mJ
per pulse. After SLT eyes were maintained with the identical hypotensive medical ther-
apy as that before treatment. IOP was measured before treatment, 1 and 7 days after
treatment and 1, 3, 6 and 12 months after treatment. The mean pretreatment IOP was
22.48 (SD 1.84) mm Hg. At the end of 1 month follow-up period the mean reduction of
IOP was 4.86 (SD 2.38) mmHg or 21.6%; after 3 months the mean reduction was 5.66
(SD 2.40) mmHg or 25.2%; after 6 months the mean reduction of IOP was 5.06 (SD 2.37)
mmHg or 22.5%; at the end of 12 months follow-up period the mean reduction was 4.92
(SD 2.58) mmHg or 21.9%. It can be concluded that SLT presents a new and effective
method of IOP reduction in the treatment of POAG.
Introduction
Selective laser trabeculoplasty (SLT)
is a new laser procedure that selectively
targets the pigmented trabecular mesh-
work (TM) cells without causing thermal
damage or collateral damage to nonpig-
mented cells or structures1. For SLT a
532-nm Q-switched frequency doubled
Nd:YAG laser is used. The precise mecha-
nism of action of SLT is unknown. Dis-
ruption or killing of pigmented TM cells
alone appears to induce a response that
results in a reduction of IOP in this
procedure2. Following the results of clini-
cal studies SLT appears to be a safe and
effective method of lowering the IOP in
eyes with primary open-angle glaucoma
(POAG)2–5. The aim of our prospective
clinical study was to investigate the IOP
111
Received for publication June 4, 2001.
reduction after SLT in the treatment of
uncontrolled POAG in patients followed
for 12 months.
Materials and Methods
Patients included in this clinical study
had POAG for which medical therapy had
failed to satisfactorily control intraocular
pressure (> 18 mmHg). All eyes were
treated with SLT. The IOP was measured
with a Goldmann applanation tonometer
at least three times in 4 weeks before la-
ser treatment was performed. The mean
preoperative IOPs was used as the base-
line IOP. On the day of SLT, IOP was
measured and one drop of 0.5% apra-
clonidine was instilled in the study eye
one hour before treatment. A 532-nm fre-
quency doubled Q-switched Nd:YAG laser
(Selecta 7000, Coherent, Palo Alto, CA,
USA) was applied to the inferior 180° of
the TM of each eye. The pulse duration
was 3 ns and the laser spot size was 400
µm. Treatment was conducted with adja-
cent but not overlapping spots. The mean
number of applied burns was 49.6 (range
47–53). The initial energy used was 0.8
mJ. The energy was increased or decrea-
sed until bubble formation appeared and
was then decreased by 0.1 mJ for the rest
of the treatment. Energies ranged from
0.40 mJ to 0.94 mJ with the mean energy
of 0.68 mJ for each spot. A drop of 0.5%
apraclonidine was instilled in all post-
laser eyes. Dexamethasone-Neomycine
eye drops were prescribed after treat-
ment four times a day for 7 days. Post-
treatment evaluation consisted of a slit
lamp examination and applanation to-
nometry performed 1 and 3 hours, 1 and 7
days, 1, 3, 6 and 12 months after treat-
ment. Hypotensive medical therapy was
not modified during 12 months follow-up
period. For statistical analyses of the re-
sults, the paired t-test was used.
Results
Fifty eyes of 28 patients were treated
with SLT. Twenty-one were females
(75%) and 7 (25%) were males. The mean
age was 71 years (range 50–84). The av-
erage number of hypotensive medications
at baseline and 12 months after treat-
ment was 2.6 (range 2–4). The baseline
IOP was 22.48 mmHg (range 18–26). The
mean IOPs, mean IOP reduction and per-
cent IOP reduction from baseline IOP 1
day, 7 days, 1 month, 3 months, 6 months
and 12 months after treatment are listed
in Table 1. The greatest decrease in IOP
occurred 3 months (25.2%) after the pro-
cedure. At the end of 12 months follow-up
period the mean reduction of IOP was
4.92 (SD 2.58). In percentage the IOP re-
duction from baseline in all treated eyes
was 21.9%.
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TABLE 1
MEAN IOP, MEAN IOP REDUCTION AND PERCENT IOP REDUCTION FROM BASELINE IOP
AT 1 AND 7 DAYS, 1, 3, 6 AND 12 MONTHS AFTER TREATMENT







Baseline IOP 22.48 /1.84/ – – –
1 day 17.36 /2.59/ 5.12 /3.08/ < 0.0001 22.8
7 days 18.44 /2.57/ 4.04 /2.61/ < 0.0001 18.0
1 month 17.62 /2.05/ 4.86 /2.38/ < 0.0001 21.6
3 months 16.82 /2.21/ 5.66 /2.40/ < 0.0001 25.2
6 months 17.42 /1.90/ 5.06 /2.37/ < 0.0001 22.5
12 months 17.56 /2.26/ 4.92 /2.58/ < 0.0001 21.9
The absolute IOP reductions from
baseline at 3 months following treatment
are listed in Table 2, at 6 months in Table
3 and at 12 months in Table 4. An abso-
lute IOP reduction of 3 mmHg or greater
was achieved in 92% of eyes at 3 months,
in 88% of eyes at 6 months and in 86% of
eyes at 12 months following treatment. A
transient increase in IOP for 1 mmHg 1
hour after treatment occurred in 3 eyes
and for 3 mmHg in 1 eye (2%). Three
hours after treatment a transient increa-
se of 2 mmHg occurred in 3 eyes (6%) and
of 4 mmHg in 1 eye (2%) for. The IOP ele-
vations were not treated with additional
antiglaucoma medications and resolved
in all cases within 12 hours. Significant
anterior segment inflammation was not
detected after SLT in any of the eyes.
None of the patients complained of pain
or any discomfort during treatment.
Discussion
Laser treatment of TM known as laser
trabeculoplasty is a commonly accepted
intervention in the management of open
angle glaucoma. Different types of lasers
with various wavelengths are used for la-
ser trabeculoplasty. Most commonly used
laser unit for trabeculoplasty is a contin-
uous-wave argon laser (454.5–528.7 nm).
It has been in use since 1979. when the
first successful protocol of argon laser
trabeculoplasty was described6. Trabecu-
loplasty can also be performed with kryp-
ton red and yellow lasers7, Q-switched
ruby laser8, continuous wave neodymium
(Nd):YAG laser9, and diode laser10.
Recently, a new approach to laser
treatment of TM by selectively targeting
pigmented TM cells without causing
thermal damage or collateral damage to
nonpigmented cells or structures and
thus maintain the architecture of the TM
was presented and termed SLT1. For SLT
a 532-nm Q-switched frequency doubled
Nd:YAG laser with a single pulse of short
duration (in the microsecond range) and
low fluency (energy/area) is used1. The
precise mechanism of action for the pres-
sure lowering effect of SLT is unknown.
Acute morphological changes evaluated
by electron microscopy in human post-
mortem eyes treated with SLT showed no
evidence of coagulative damage and mini-
mal evidence of mechanical damage to
human TM11. However, since minimal
mechanical damage is thought to occur, a
predominately cellular theory, as the me-
chanism of action, has been proposed to
explain an improvement in outflow facil-
ity in eyes treated with SLT2. Thus, a
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TABLE 3
ABSOLUTE IOP REDUCTION FROM
BASELINE AT 6 MONTHS
IOP Reduction
(mmHg from baseline)





ABSOLUTE IOP REDUCTION FROM
BASELINE AT 3 MONTHS
IOP Reduction
(mmHg from baseline)






ABSOLUTE IOP REDUCTION FROM
BASELINE AT 12 MONTHS
IOP Reduction
(mmHg from baseline)





Q-switched Nd:YAG laser for SLT in the
clinical practice was proposed as a new
laser treatment for POAG11.
In our prospective clinical study we in-
vestigated the IOP reduction after SLT
treatment in 50 eyes with uncontrolled
POAG. We found that the IOP reduction
after SLT is achieved immediately – 1
day after treatment, with the mean IOP
reduction of 5.12 mmHg (22.8%) from the
baseline pretreatment level in all treated
eyes. After 6 months follow-up the IOP
reduction from baseline in all treated
eyes was 5.06 mmHg (22.5%). After 12
months follow-up the IOP reduction from
the baseline in all treated eyes remained
stable and was 4.92 mmHg (21.9%). We
also found, that the absolute IOP reduc-
tion of 3 mmHg or greater was achieved
in 92% of eyes at 3 months after treat-
ment and in 88% of eyes at 6 months after
treatment. At 12 months after treatment
86% of eyes achieved an absolute IOP re-
duction of 3 mmHg. These results are
comparable with the results of Latina et
al2, who, in their prospective clinical trial
with 53 uncontrolled POAG eyes after
SLT, reported the absolute IOP reduction
of 3 mmHg or greater in 70% of treated
eyes and after the follow-up period of 6
months in 44 eyes the mean IOP reduc-
tion of 4.6 mmHg (18.7%). Damji et al4 re-
ported the mean IOP reduction of 4.8
mmHg after the follow-up period of 6
months in 18 eyes with uncontrolled
POAG after treatment with SLT. Kaulen
et al5 studied a larger number of treated
eyes – 224 eyes with uncontrolled POAG
treated with SLT. The follow-up period
was 10 months (range 1–20) and the
mean IOP reduction was 6 mmHg (23%).
In the study of Latina et al2 an increase
in IOP 2 hours after treatment for 5
mmHg or greater was detected in 18 eyes
(34%) and the anterior segment inflam-
mation in 44 eyes (83%). Lanzetta et al3
detected in only one eye (12.5%) 1 hour
after treatment an increase of IOP
greater than 5 mmHg, without any sig-
nificant anterior segment inflammation.
In those two studies pre- and posttreat-
ment eyes were not on medication regi-
men of 0.5 % apraclonidine and the en-
ergy levels ranged from 0.6 to 1.2 mJ per
pulse. Damji et al4 detected significant
anterior segment inflammation after
treatment with no posttreatment IOP el-
evations. 1-% apraclonidine pre- and post-
treatment was used and the energy levels
ranged from 0.8 to 1.4 mJ per pulse.
In our study the transient IOP in-
crease 1 to 3 hours after treatment was
not significant. It occurred in 8 eyes
(16%) and was not greater than 4 mmHg.
Significant anterior segment inflamma-
tion after SLT was not detected. We think
this is a result of pre- and posttreatment
use of one drop of 0.5% apraclonidine and
low energies used: between 0.40 and 0.94
mJ with the mean energy of 0.68 mJ for
each spot.
The results of our study proved SLT to
be an effective and safe method for IOP
reduction in the treatment of POAG. To
investigate the duration of IOP lowering
effect we need a long-term follow-up pro-
spective clinical study.
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SMANJENJE INTRAOKULARNOG TLAKA NAKON SELEKTIVNE
LASERSKE TRABEKULOPLASTIKE KOD PRIMARNOG GLAUKOMA
OTVORENOG KUTA – 12-MJESE^NO PRA]ENJE
S A @ E T A K
Cilj ovog istra`ivanja bio je ispitati smanjenje intraokularnog tlaka nakon selek-
tivne laserske trabekuloplastike (SLT) kod pacijenata s primarnim glaukomom otvo-
renog kuta (POAG) u prospektivnoj klini~koj studiji. SLT predstavlja novu metodu u
lije~enju primarnog glaukoma otvorenog kuta. Pedeset o~iju s nekontroliranim primar-
nim glaukomom otvorenog kuta tretirano je dvostrukofrekventno »Q-switched« Nd-YAG
laserom (532 nm). Ukupan broj od oko 50 nepreklapaju}ih spotova energetske razine u
rasponu od 0.40 do 0.92 mJ po pulsu aplicirano je na 180 stupnjeva trabekularnog
aparata. Nakon SLT-a primjenjivana je istovjetna medikamentna hipotenzivna tera-
pija kao i prije zahvata. Intraokularni tlak mjeren je prije tretmana, te nakon 1 i 7
dana, te 1,3,6 i 12 mjeseci. Srednja vrijednost intraokularnog tlaka prije zahvata izno-
sila je 22.48 (SD 1.84) mmHg. Na kraju prvog mjeseca pra}enja vrijednost intraoku-
larnog tlaka smanjila se u prosjeku za 4.86 (SD 2.38) mmHg ili 21.6%; nakon 3 mjeseca
za prosje~no 5.66 (SD 2.40) mmHg ili 25.2%; nakon 6 mjeseci za prosje~no 5.06 (SD
2.37) mmHg ili 22.5% te na kraju 12-mjese~nog perioda pra}enja za 4.92 (SD 2.58)
mmHg ili 21.9%. Mo`emo zaklju~iti da SLT predstavlja novu djelotvornu metodu za
smanjenje intraokularnog tlaka u lije~enju primarnog glaukoma otvorenog kuta.
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